Clinical Features and Outcome of Low and High Corticosteroids in Admitted COVID-19 Patients

Abstract

Introduction:There is no specific anti-viral therapies for 2019 Coronavirus Diseases (COVID-19) infection. Here, we compared patients receiving steroids at different dosages versus no steroids in severe and critical COVID-19 patients. Methods:We retrospectively studied COVID-19 patients who received low-dose or high-dose corticosteroid therapy compared to no steroid. Results:The study period, June-August 2020, included 169 patients with COVID-19 were included and there were 39.1% female and 60.9% male with an average age of 53.1 years. The distribution of cases was as follows: high-dose 39 (23.1%), low-dose 54 (32.0%), and no steroid 76 (45.5%). Of all the patients, Intensive Care Unit (ICU) admission was for 31 (18.3%), nine (5.3%) required intubation, and 52 (30.8%) had no comorbidities. There is no difference in the mean age between the different groups. However, those being treated with steroid were more likely to have a high SOFA score (0.37 ± 0.68, 0.36 ± 0.67 and 0.04 ± 0.34, for low-dose, high-dose steroid and no steroid groups, respectively (p = 0.001). Cox regression was not possible as the mortality rate was very low (3/169; 1.78%) and none of the multivariate methods would be possible. However, there was a significant difference in the hospital LOS and the ICU LOS. Conclusion:Cox regression was not possible as the mortality rate was very low (1.78%) and none of the multivariate methods would be possible as the model will not converge. However, in t-test only, intubation was associated risk of mortality.

Comorbid Asthma Increased the Risk for COVID-19 Mortality in Asia: A Meta-Analysis

“…After that, 300 articles were evaluated for full-text eligibility, and 197 articles with available data but not Asian were excluded. Ultimately, 103 studies conducted in Asia were enrolled in this meta-analysis [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 ,…”

Initial viral cycle threshold values in patients with COVID-19 and their clinical significance

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had resulted in a global pandemic with increasing number of cases and associated death [1]. The Kingdom of Saudi Arabia had also been involved with pandemic as early as March 2020 with the implementation of multiple steps to combat the pandemic [2][3][4]. There are many studies showing the risk of increased disease severity such as: age, body mass index (BMI), underlying medical diseases, clinical signs and symptoms, and laboratory data [5,6].…”

Mucomycoses identified using the COVID-19 health impacts with mucomycoses consider the COVID-19

“…Despite this, India has the second-highest population of diabetics in the world 6 . The most common causes of death linked with mucormycosis in Europe and the United States are hematological malignancies and organ transplantation 7 . Diabetes mellitus is the leading cause of mucormycosis worldwide because of its high death rate.…”